Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer

on behalf of AstraZeneca UK Limited

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
64 Downloads (Pure)


The type of patients with stage III non-small-cell lung cancer (NSCLC) selected for concurrent chemoradiotherapy (cCRT) varies between and within countries, with higher-volume centres treating patients with more co-morbidities and higher-stage disease. However, in spite of these disease characteristics, these patients have improved overall survival, suggesting that there are additional approaches that should be optimised and potentially standardised. This paper aims to review the current knowledge and best practices surrounding treatment for patients eligible for cCRT. Initially, this includes timely acquisition of the full diagnostic workup for the multidisciplinary team to comprehensively assess a patient for treatment, as well as imaging scans, patient history, lung function and genetic tests. Such information can provide prognostic information on how a patient will tolerate their cCRT regimen, and to perhaps limit the use of additional supportive care, such as steroids, which could impact on further treatments, such as immunotherapy. Furthermore, knowledge of the safety profile of individual double-platinum chemotherapy regimens and the technological advances in radiotherapy could aid in optimising patients for cCRT treatment, improving its efficacy whilst minimising its toxicities. Finally, providing patients with preparatory and ongoing support with input from dieticians, palliative care professionals, respiratory and care-of-the-elderly physicians during treatment may also help in more effective treatment delivery, allowing patients to achieve the maximum potential from their treatments.

Original languageEnglish
Pages (from-to)28-35
JournalBritish Journal of Cancer
Issue numberSupplement 1
Publication statusPublished - 01 Dec 2020


  • Lung Cancer
  • Treatment
  • Radiotherapy
  • Chemotherapy
  • Stage 3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this